Contact UsBiological Products
> Biopharmaceutical Industry Insight & News > Biological Products
| Product | BRENZYS? | Company | Samsung Bioepis |
|---|---|---|---|
| Classification | Biosimilar | Active Ingredient | Etanercept |
| Reference Product | Enbrel | Approval Date | 2015 |
| Indication | [Korea] Rheumatoid arthritis, Psoriatic arthritis, Axial spondyloarthritis (Ankylosing spondylitis and non-radiographic axial spondyloarthritis), Plaque psoriasis | ||
| Description |
Following an approval in Sep 2015 in Korea, it was approved in EU (Jan 2016), Australia (Jul 2016) and Canada (Aug 2016)
BRENZYS? is a fusion protein which inhibits turnor necrosis factor alpha, known to modulate immune responses. * BRENZYS? is commerciallized in EU as BENEPALI?. |
||
Korea Biomedicine Industry Association(KoBIA)
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
COPYRIGHT BY KoBIA. ALL RIGHTS RESERVED.